The company's lead drug candidate, asimadoline, is an orally administered small molecule drug that is being developed for the treatment of irritable bowel syndrome and functional dyspepsia. It has shown an acceptable safety profile and does not have mu-opioid like side-effects. Tioga Pharmaceuticals, founded in 2005 and based in San Diego, California, is currently conducting Phase 3 clinical trials for asimadoline in the treatment of diarrhea-predominant irritable bowel syndrome (D-IBS). Their goal is to provide novel therapies for gastrointestinal diseases, including irritable bowel syndrome and post-operative ileus.